$BIAF

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL Companies debut federal distribution collaboration to VA leadership, administrators a

BioAffinity Technologies (NASDAQ:BIAF) shares rose 50.47% to $8.05 Thursday after receiving a Hong Kong patent for its CyPath Lung diagnostic. The patent complements a 2025 patent in China, covering a region with high lung cancer incidence. CyPath Lung has shown strong clinical performance, with 92% sensitivity and 87% specificity in trials. The company's warrants (NASDAQ:BIAFW) also gained nearly 20%.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath ® Lung Noninvasive Lung Cancer Diagnostic Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds o

U.S. stocks fell Tuesday, with the Dow Jones dropping 450 points. The NFIB Small Business Optimism Index declined to 98.7 in August. PDS Biotechnology (PDSB) shares surged 178% after raising $22.55 million in equity funding. Energy shares rose 1.4%, while healthcare stocks fell 2.2%.

bioAffinity Technologies (BIAF) rose 47.95% after announcing its AI-based lung-cancer surveillance tool, CyPath Lung, and a 1-for-15 reverse stock split. Q2 test volume surged 216% YoY, but the company reported a $3.4M net loss and $2.4M cash. Clinical study results showed 92% sensitivity and 88% accuracy. The company faces challenges in scaling revenue and managing dilution risks.

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

BioAffinity Technologies (BIAF) shares rose 40% after announcing plans to expand use of its CyPath Lung test for lung cancer surveillance. The stock traded at $6.40, up from $4.56, with high volume.

BioAffinity Technologies (BIAF) signed a nationwide distribution agreement with AvMEDICAL to expand access to its CyPath Lung diagnostic test in federal healthcare agencies. The partnership leverages AvMEDICAL's government procurement expertise. BIAF stock closed at $0.47, down 11.24% in pre-market trading.

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules SAN ANTONIO, TX – August 13, 2026 – bioAffinity Technologies, Inc . (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical